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Background:  A rotavirus  vaccine  could  soon  become  part of  India’s  national  immunization  program.
However  the  occurrence  of  intussusception  due  to  rotavirus  vaccine  is  a  potential  safety  concern.  This
surveillance  aimed  at the  collection  of baseline  data  on  childhood  intussusception  which  would  facilitate
the  monitoring  of  intussusception  cases  after  the  introduction  of  rotavirus  vaccines.
Methods:  We  retrospectively  reviewed  medical  records  of  conﬁrmed  intussusception  cases  in  children
under  the  age  of ﬁve,  treated  during  2007–2012  at two tertiary  care  hospitals  attached  to  medical  schools
in  India.  Demographic,  clinical,  diagnostic  and  treatment  practices  data  were  obtained  from  hospital
records.
Results:  Over  a ﬁve  to six  year observation  period,  we identiﬁed  187  conﬁrmed  cases  of intussusception,
of  which  75%  were  males.  The  median  age  of intussusception  was  8 months,  and  we observed  a possible
trend  in  the  distribution  of cases  with  the highest  number  of cases  being  reported  in  the  month  of  April
and  lowest  in  the month  of October.  The  most  common  diagnostic  methods  used were  ultrasonography
and  abdominal  radiography  with  most  cases  being  treated  surgically  (71%).  The  median  length  of hospital
stay  was  8 days  (range  1–40)  and  mean  was  10.2  days. Records  of any  fatality  due to  intussusception  were
not  found  during  the review  of  the  records.
Conclusions:  This  analysis  provides  an estimate  of  the baseline  data  of childhood  intussusception  prior
to  the  introduction  of  the  rotavirus  vaccination  as a part of  routine  immunization  in  India.  A prospec-
tive  surveillance  system  using  a standardized  case  deﬁnition  is  needed  in  order  to  better  examine  the
incidence  of  intussusception  in  developing  countries.
d  by ©  2014  Publishe
. Introduction
Intussusception is characterized by a sudden onset of abdomi-
al pain, vomiting, rectal bleeding, and the presence of a palpable
bdominal mass. These signs and symptoms are caused by bowel
bstruction due to invagination of a segment of intestine into the
djoining intestinal lumen. The condition is diagnosed by ultra-
onography, radiology or surgery, and is usually treated by air or
ydrostatic reduction enema under radiologic or ultrasound guid-
nce.
However, surgery may  be required in some cases, and approxi-
ately 10% of patients with intussusception undergo an intestinal
∗ Corresponding author at: Shantha Biotechnics Limited, 3rd and 4th Floor, Vas-
ntha Chambers, #5-10-173, Fateh Maidan Road, BasheerBagh, Hyderabad 500004,
P,  India. Tel.: +91 40 66301000.
E-mail address: MandeepSingh.Dhingra@sanoﬁ.com (M.S. Dhingra).
ttp://dx.doi.org/10.1016/j.vaccine.2014.03.007
264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC BElsevier  Ltd.  This  is an  open  access  article  under the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
resection due to a vascular injury to the intestine. Intussuscep-
tion primarily affects children, with the peak incidence reported
between 4 and 10 months of age [1]. The background incidence and
case fatality vary widely by region, and deaths from intussusception
are more common in developing than in industrialized countries
[2].
As per Global Enteric Multicenter Study (GEMS) conducted in
low income countries, the estimated incidence of moderate-to-
severe diarrhea is highest in India [3]. Worldwide in 2008, diarrhea
attributable to rotavirus infection resulted in 453,000 deaths (95%
CI 420,000–494,000) in children younger than 5 years; 37% of
deaths attributable to diarrhea and 5% of all deaths in children
younger than 5 years. Five countries accounted for more than
half of all deaths attributable to rotavirus infection: Democratic
Republic of the Congo, Ethiopia, India, Nigeria, and Pakistan; India
alone accounted for 22% of deaths (98,621 deaths) [4] .One of the
safety concern for rotavirus vaccines as they are introduced in
routine childhood immunization programs is the occurrence of
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ntussusception, a serious intestinal condition that occurs natu-
ally in infancy at a relative low frequency [5]. An earlier vaccine
Rotashield®, Wyeth Vaccines, USA) based on a different (rhesus)
train than the current WHO  recommended vaccines was found to
e associated with an increased risk of intussusception [6]. For the
urrent vaccines, large clinical trials did not ﬁnd an increased risk
f intussusception at a level similar to that seen with the previous
hesus vaccine [7,8].
As in many other emerging economies, sufﬁcient background
ata on incidence and epidemiology of intussusception is unavail-
ble in India. At present there are three rotavirus vaccines under
evelopment in India by local Indian manufacturers and since all
hree of them may  ultimately be used as a part of public health
ystem in India and intended for a widespread global use by the
irtue of a WHO  pre-qualiﬁcation, there is an urgent need to gen-
rate baseline data related to intussusception from India. In light of
his, we undertook a retrospective surveillance at two  tertiary care
enters in India to collect local data on the baseline characteristics
nd epidemiology of intussusception to support post introduction
afety monitoring.
. Method
.1. Study area and participating hospitals
This retrospective hospital-based analysis reviewed cases of
ntussusception documented in the medical records during the
ears 2007–2012, at two centers attached to Medical Schools
n India. From southern India, Kasturba Medical College (KMC),
anipal (2007–2011), and from north-central India CSM Medical
niversity (CSMMU), Lucknow (2007–2012) were involved in this
tudy. Necessary permission was obtained at each of the hospi-
als to facilitate the review of patient medical records by the local
tudy teams. Patient conﬁdentiality was respected during the com-
ilation and analysis of the data.
.2. Case deﬁnition and data sources
Surveillance to identify cases of intussusception was  planned
or at least ﬁve complete years. Children ≤60 months of age with
onﬁrmed diagnosis of intussusception, using the case deﬁnition
eveloped by the Brighton Collaboration Working Group, from
anuary 2007 through December 2012 were eligible for inclusion
n the database. [9].
Patients at Level 1 of diagnostic certainty were deﬁned as con-
rmed cases. Level 1 requires one of the following: demonstrationases in children aged less than 5 years
of invagination of the intestine at surgery and/or by either air or
liquid-contrast enema, presence of intra-abdominal mass on ultra-
sonography, and/or the demonstration of invagination at autopsy.
Cases diagnosed using a combination of clinical symptoms and
signs according to Levels 2 and 3 of diagnostic certainty are deﬁned
as probable. Suspected cases are patients with a diagnosis of intus-
susception for whom the available information prevents from
determining the level of diagnostic certainty. Data for each identi-
ﬁed case was  collected by reviewing admission and discharge logs,
case history records, ultrasonography, radiology logs, and surgery
reports from the respective hospitals.
2.3. Data collection and analysis
For this study, baseline data of conﬁrmed cases of intussuscep-
tion only was  collected. For each identiﬁed child, information on
demographics, admission and discharge dates, clinical signs and
symptoms and their duration, as well as diagnostic and treatment
procedures performed was extracted, recorded on pre-developed
case record forms and then entered into an MS  Excel database.
Symptoms and signs were recorded as positive or negative only if
the presence or absence of the symptom or sign was documented
by the medical and/or nursing staff in the patient’s records. The data
was pooled and analyzed according to age, sex, clinical signs, year
and month of hospitalization, and diagnostic and treatment-related
characteristics.
3. Results
During the surveillance, we identiﬁed 187 conﬁrmed cases of
intussusception in children less than 60 months (5 years) of age. The
median age of diagnosis was  8 months (range 1.5–60). The major-
ity of cases diagnosed were below the age of 12 months (55.6%)
with the highest number of cases in the age group of 6–11 months
(31.6%) (Fig. 1).
We  identiﬁed a male–female ratio of 3.1:1, with males account-
ing for 75% and females 25% of conﬁrmed intussusception cases.
We  found the highest numbers of cases of intussusception in
the month of April and lowest numbers in the month of September
(Fig. 2).
The study observed that the most frequent symptoms were
recurrent vomiting (51.3%) and abdominal pain (47%). Other symp-
toms recorded include: blood in stool (18.7%), abdominal distension
(12.3%), excessive crying (13.4%) and fever (6.4%). We documented
the classic triad of vomiting, passage of blood through the rectum
and abdominal pain in 18.7% of children.
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To diagnose intussusception ultrasonography was  used in 71.6%
f cases and plain abdominal radiography in 25.6% of cases. Of the
87 conﬁrmed cases, 134 cases (71.65%) were managed surgically,
8 cases (25.66%) managed by radiological reduction and sponta-
eous recovery occurred in 5 cases (2.67%). The mean duration
f hospital stay for cases of intussusception was 10.2 days with
edian of 8 days (range 1–40). No record of fatality due to intus-
usception was found in the records for the deﬁned review period.
n an average 17.3 cases of conﬁrmed intussusception were iden-
iﬁed from this retrospective analysis. At CSMMU, Lucknow atleast
4 cases per year were recorded over a duration of six years while
t KMC, Manipal atleast 20 cases per year were recorded over a
uration of ﬁve years.
. Discussion
This analysis describes the epidemiological characteristics of
ntussusception in two regions of India. Epidemiology of intussus-
eption in India is similar to that described in other parts of the
orld. Previous reports specify that this condition is more frequent
n males, with our study yielding a male to female ratio of 3.1:1.
hile the ratio varies widely across different countries, all reports
ndicated predominance of males. In the geographically close Asian
egion, studies report this ratio to range from 1.3:1 in Singapore [10]
o 9:1 in India [11,12].
A possible trend, with highest cases reported in the month of
pril was observed. This is in contrast to reports from other studies
n which no such trend was reported [13–15]. A peak of diagno-
is (maximum number of cases) was observed in infants between 6
nd 12 months of age. In this analysis, the classic triad of abdominal
ain, vomiting, and rectal bleeding was reported in 18.7% of sub-
ects which is higher than reported in a similar study conducted in
ndia [14]. However, we found that clinical signs and symptoms in
he present analysis were similar to those reported previously in
ther studies [14,15]. Vomiting was the most commonly recorded
linical symptom. We  found that most of the cases were managed
urgically which imposes a heavy economic burden on the health
ystem in terms of prolonged hospital stay however this observa-
ion caries a potential bias as both the hospitals were tertiary care
enters where relatively serious cases are seen.
The current study was limited by the lack of complete immu-
ization data which made it difﬁcult to reliably count the number
nd type of immunizations administered prior to hospitalizations in children aged less than 5 years.
for intussusception. Additionally, the analysis was limited by the
inability to deﬁne the catchment area for intussusception cases
or to obtain accurate birth-cohort data for the catchment popula-
tion. As data collected was  from referral hospitals, these cases were
those that were most severe and may  not be representative of all
cases identiﬁed through population surveillance This prevented the
estimation of incidence of intussusception cases in a population.
Nevertheless, the strength of this retrospective study is that
it provides important insights into the epidemiology of intussus-
ception among Indian children belonging to two different regions.
Although the next generation of licensed rotavirus vaccines, in
large clinical trials did not ﬁnd an increased risk of intussuscep-
tion at a level similar to that seen with the previous rhesus vaccine,
but this needs to be re-established in post-marketing surveillances
which would provide further conﬁrmation of their safety. This anal-
ysis would be useful in terms of baseline data to facilitate further
surveillance.
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